Baxter International Inc. Q3 2025 Earnings Recap

BAX Q3 2025 October 31, 2025

Get alerts when BAX reports next quarter

Baxter International's Q3 2025 results showed lower-than-expected revenue but exceeded earnings forecasts driven by a favorable tax rate, while new CEO Andrew Hider emphasizes a commitment to operational improvements and financial health.

Earnings Per Share Beat

$0.69 vs $0.60 est.

+15.0% surprise

Revenue Beat

2835000000 vs 2824802960 est.

+0.4% surprise

Market Reaction

1-Day -1.41%

5-Day -2.54%

30-Day +2.27%

See BAX alongside your other holdings

Add to your portfolio — free

Key Takeaways

Revenue performance fell short of guidance primarily due to challenges in the Infusion Therapies & Technologies and Pharmaceuticals divisions.
The Healthcare Systems & Technologies segment showed improved performance, indicating potential resilience in key areas.
The company plans to stabilize underperforming divisions, strengthen its balance sheet, and cultivate a culture of continuous improvement.
Baxter aims to address operational issues, particularly regarding the Novum IQ Large Volume pump, which faces a delivery hold due to flow rate concerns.
Moving forward, a clear focus on cash flow improvement and reducing leverage is prioritized to support growth and shareholder returns.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit BAX on AllInvestView.

Next Q1 2026